Skip to main content
SpringerLink
Log in

Malignant transformation by abl and BCR/ABL

  • Chapter
Oncogenes and Tumor Suppressor Genes in Human Malignancies

Part of the book series: Cancer Treatment and Research ((CTAR,volume 63))

Abstract

Activated abl oncogenes have been implicated in causing pre-B lymphoma in mice via Abelson murine leukemia virus, fibrosarcoma in cats via Hardy-Zuckerman feline sarcoma virus II, and, through the Philadelphia chromosome, are linked with the myeloproliferative syndrome chronic myelogenous leukemia and with acute lymphoid and myeloid leukemia in humans. This review will outline the current state of knowledge concerning this important oncogene family, emphasizing recent advances in our understanding.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rosenberg N, Witte ON: The viral and cellular forms of the abelson (abl) oncogene. In: Advances in Virus Research. Academic Press, 1988, pp 39–81.

    Google Scholar 

  2. Abelson HT, Rabstein LS: Lymphosarcoma: Virus-induced thymic-independent disease in mice. Cancer Res 30:2213–2222, 1970.

    PubMed  CAS  Google Scholar 

  3. Scher CD, Siegler R: Direct transformation of 3T3 cells by Abelson murine leukemia virus. Nature 253:729–731, 1975.

    PubMed  CAS  Google Scholar 

  4. Green PL, Kaehler DA, Risser R: Cell transformation and tumor induction by Abelson murine leukemia virus in the absence of helper virus. Proc Natl Acad Sci USA 84:5932–5936, 1987.

    PubMed  CAS  Google Scholar 

  5. Risser R, Potter M, Rowe WP: Abelson virus-induced lymphomagenesis in mice. J Exp Med 148:714–726, 1978.

    PubMed  CAS  Google Scholar 

  6. Tidmarsh GF, Heimfeld S, Whitlock CA, Weissman IL, Muller-Sieburg CE: Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for abelson leukemia virus targets. Mol Cell Biol 9:2665–2671, 1989.

    PubMed  CAS  Google Scholar 

  7. Alt F, Rosenberg N, Lewis S, Thomas E, Baltimore D: Organization and reorganization of immunoglobulin genes in A-MuLV-transformed cells: Rearrangement of heavy but not light chain genes. Cell 27:381–390, 1981.

    PubMed  CAS  Google Scholar 

  8. Rosenberg N, Baltimore D, Scher CD: In vitro transformation of lymphoid cells by abelson murine leukemia virus. Proc Natl Acad Sci USA 72:1932–1936, 1975.

    PubMed  CAS  Google Scholar 

  9. Potter M, Sklar MD, Rowe WP: Rapid viral induction of plasmacytomas in pristane-primed BALB/c mice. Science 182:592–594.

    Google Scholar 

  10. Raschke WC, Baird S, Ralph P, Nakoinz I: Functional macrophage cell lines transformed by abelson leukemia virus. Cell 15:261–267, 1973.

    Google Scholar 

  11. Pierce JH, Di Fiore PP, Aaronson SA, Potter M, Pumphrey J, Scott A, Ihle JN: Neoplastic transformation of mast cells by abelson-MuLV: Abrogation of IL-3 dependence by a nonautocrine mechanism. Cell 41:685–693, 1985.

    PubMed  CAS  Google Scholar 

  12. Cook WD: Rapid thymomas induced by Abelson murine leukemia virus. Proc Natl Acad Sci USA 79:2917–2921, 1982.

    PubMed  CAS  Google Scholar 

  13. Waneck GL, Rosenberg N: Abelson leukemia virus induces lymphoid and erythroid colonies in infected fetal cell cultures. Cell 26:79–89, 1981.

    PubMed  CAS  Google Scholar 

  14. Chung S-W, Ruscetti S, Wong PMC: Formation of factor-independent hematopoietic multilineage colonies after abelson virus infection. Blood 71:973–977, 1988.

    PubMed  CAS  Google Scholar 

  15. Cook WD, De St. Groth BF, Miller JFAP, MacDonald HR, Gabathuler R: Abelson virus transformation of an interleukin 2-dependent antigen-specific T-cell line. Mol Cell Biol 7:2631–2635, 1987.

    PubMed  CAS  Google Scholar 

  16. Mathey-Prevot B, Nabel G, Palacios R, Baltimore D: Abelson virus abrogation of interleukin-3 dependence in a lymphoid cell line. Mol Cell Biol 6:4133–4135, 1986.

    PubMed  CAS  Google Scholar 

  17. Cook WD, Metcalf D, Nicola NA, Burgess AW, Walker F: Malignant transformation of a growth factor-dependent myeloid cell line by abelson virus without evidence of an autocrine mechanism. Cell 41:677–683, 1985.

    PubMed  CAS  Google Scholar 

  18. Shields A, Goff S, Paskind M, Otto G, Baltimore D: Structure of the abelson murine leukemia virus genome. Cell 18:955–962, 1979.

    PubMed  CAS  Google Scholar 

  19. van de Ven WJ, Reynolds FH, Nalewaik RP, Stephenson JR: The nonstructural component of the Abelson murine leukemia virus polyprotein pl20 is encoded by newly acquired genetic sequences. J Virol 32:1041–1045, 1979.

    PubMed  Google Scholar 

  20. Witte ON, Rosenberg NE, Baltimore D: A normal cell protein cross-reactive to the major abelson murine leukaemia virus gene product. Nature 5730:396–398, 1979.

    Google Scholar 

  21. Goff SP, Gilboa E, Witte ON, Baltimore D: Structure of the abelson murine leukemia virus genome and the homologous cellular gene: Studies with cloned viral DNA. Cell 22–777–785, 1980.

    Google Scholar 

  22. Reddy EP, Smith MJ, Srinivasan A: Nucleotide sequence of Abelson murine leukemia virus genome: Structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity. Proc Natl Acad Sci USA 80:3623–3627, 1983.

    PubMed  CAS  Google Scholar 

  23. Bishop JM: Cellular oncogenes and retroviruses. Ann Rev Biochem 52:301–354, 1983.

    PubMed  CAS  Google Scholar 

  24. Schultz A, Oroszlan S: Myristylation of gag-one fusion proteins in mammalian transforming retroviruses. Virology 133:431–437, 1984.

    PubMed  CAS  Google Scholar 

  25. Witte ON, Ponticelli A, Gifford A, Baltimore D, Rosenberg N, Elder J: Phosphorylation of the abelson murine leukemia virus transforming protein. J Virol 39:870–878, 1981.

    PubMed  CAS  Google Scholar 

  26. Sefton BM, Hunter T, Raschke WC: Evidence that the Abelson virus protein function in vivo as a protein kinase that phosphorylates tyrosine. Proc Natl Acad Sci USA 78:1552–1556, 1981.

    PubMed  CAS  Google Scholar 

  27. Witte ON, Goff S, Rosenberg N, Baltimore D: A transformation-defective mutant of abelson murine leukemia virus lacks protein kinase activity. Proc Natl Acad Sci USA 77:4993–4997.

    Google Scholar 

  28. Prywes R, Foulkes JG, Baltimore D: The minimum transforming region of v-abl is the segment encoding protein-tyrosine kinase. J Virol 54:114–122, 1985.

    PubMed  CAS  Google Scholar 

  29. Engelman A, Rosenberg N: Isolation of temperature-sensitive Abelson virus mutants by site-directed mutagenesis. Proc Natl Acad Sci USA 84:8021–8025, 1987.

    PubMed  CAS  Google Scholar 

  30. Kipreos E, Lee GJ, Wang JYJ: Isolation of temperature-sensitive tyrosine kinase mutants of v-abl oncogene by screening with antibodies for phosphotyrosine. Proc Natl Acad Sci USA 84:1345–1349, 1987.

    PubMed  CAS  Google Scholar 

  31. Boss MA, Dreyfuss G, Baltimore D: Localization of the abelson murine leukemia virus protein in a detergent-insoluble subcellular matrix: Architecture of the protein. J Virol 40:472–481, 1981.

    PubMed  CAS  Google Scholar 

  32. Rohrschneider LR, Najita LM: Detection of the v-abl gene product at cell-substratum contact sites in Abelson murine leukemia virus-transformed fibroblasts. J Virol 51:547–552, 1984.

    PubMed  CAS  Google Scholar 

  33. Van Etten RA, Jackson P, Baltimore D: The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669–678, 1989.

    PubMed  Google Scholar 

  34. Cross FR, Garber EA, Pellman D, Hanafusa H: A short sequence in the p60src N terminus is required for p60src myristylation and membrane association and for cell transformation. Mol Cell Biol 4:1834–1842, 1984.

    PubMed  CAS  Google Scholar 

  35. Daley GQ, Van Etten RA, Jackson PJ, Bernards A, Baltimore D: Non-myristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol Cell Biol 12:1864–1871, 1992.

    PubMed  CAS  Google Scholar 

  36. Kamps MP, Buss JE, Sefton BM: Rous sarcoma virus transforming protein lacking myristic acid phosphorylates known polypeptide substrates without inducing transformation. Cell 45:105–112, 1986.

    PubMed  CAS  Google Scholar 

  37. Green PL, Kaehler DA, McKearn J, Risser R: Substitution of the LTR of Abelson murine leukemia virus does not alter the cell type of virally induced tumors. Oncogene 2:383–392, 1988.

    Google Scholar 

  38. Daley GQ, Van Etten RA: Unpublished observations.

    Google Scholar 

  39. Besmer P, Hardy WD, Zuckerman EE, Bergold P, Lederman L, Snyder HW, Jr.: The Hardy-Zuckerman 2-FeSV, a new feline retrovirus with oncogene homology to Abelson-MuLV. Nature 303:825–828, 1983.

    PubMed  CAS  Google Scholar 

  40. Bergold PJ, Blumenthal JA, D’Andrea E, Snyder HW, Lederman L, Silverstone A, Nguyen H, Besmer P: Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert. J Virol 61:1193–1202, 1987.

    PubMed  CAS  Google Scholar 

  41. Wang JYJ, Ledley F, Goff S, Lee R, Groner Y, Baltimore D: The mouse c-abl locus: Molecular cloning and characterization. Cell 36:349–356.

    Google Scholar 

  42. Bernards A, Rubin CM, Westbrook CA, Paskind M, Baltimore D: The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Mol Cell Biol 7:3231–3236, 1984.

    Google Scholar 

  43. Wang JYJ, Baltimore D: Cellular RNA homologous to the abelson murine leukemia virus transforming gene: Expression and relationship to the viral sequence. Mol Cell Biol 3:773–779, 1983.

    PubMed  CAS  Google Scholar 

  44. Oppi C, Shore SK, Reddy EP: Nucleotide sequence of testis-derived c-abl cDNAs: Implications for testis-specific transcription and abl oncogene activation. Proc Natl Acad Sci USA 84:8200–8204, 1987.

    PubMed  CAS  Google Scholar 

  45. Ben-Neriah Y, Bernards A, Paskind M, Daley GQ, Baltimore D: Alternative 5’ exons in c-abl mRNA. Cell 44:577–586, 1986.

    PubMed  CAS  Google Scholar 

  46. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E: Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 47:277–284, 1986.

    PubMed  CAS  Google Scholar 

  47. Hanks SK, Quinn AM, Hunter T: The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 241:42–52, 1988.

    PubMed  CAS  Google Scholar 

  48. Kruh GD, King CR, Kraus MH, Popescu NC, Amsbaugh SC, McBride WO, Aaronson SA: A novel human gene closely related to the abl proto-oncogene. Science 234:1545–1548, 1986.

    PubMed  CAS  Google Scholar 

  49. Kruh GD, Perego R, Miki T, Aaronson SA: The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases. Proc Natl Acad Sci USA 87:5802–5806, 1990.

    PubMed  CAS  Google Scholar 

  50. Henkemeyer MJ, Bennett RL, Gertler FB, Hoffmann FM: DNA sequence, structure, and tyrosine kinase activity of the Drosophila melanogaster abelson proto-oncogene homolog. Mol Cell Biol 8:843–853, 1988.

    PubMed  CAS  Google Scholar 

  51. Gertler FB, Bennett RL, Clark MJ, Hoffmann FM: Drosophila abl tyrosine kinase in embryonic CNS axons: A role in axonogenesis is revealed through dosage-sensitive interactions with disabled. Cell 58:103–113, 1989.

    PubMed  CAS  Google Scholar 

  52. Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S, Harbison ML, Robertson EJ, Goff SP: Mice homozygous for the abl ml mutation show poor viability and depletion of selected B and T cell populations. Cell 65:1165–1176, 1991.

    PubMed  CAS  Google Scholar 

  53. Tybulewicz VLJ, Crawford CE, Jackson PK, Mulligan RC: Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl protooncogene. Cell 65:1153–1164, 1991.

    PubMed  CAS  Google Scholar 

  54. Towler DA, Eubanks SR, Towery DS, Adams SP, Glaser L: Amino-terminal processing of proteins by N-myristoylation. J Biol Chem 262:1030–1036, 1987.

    PubMed  CAS  Google Scholar 

  55. Jackson P, Baltimore D: N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J 8:449–456, 1989.

    PubMed  CAS  Google Scholar 

  56. Shaw AS, Amrein KE, Hammond C, Stern DF, Sefton BM, Rose JK: The lck tyrosine protein kinase interacts with the cytoplasmic tail of the CD4 glycoprotein through its unique amino-terminal domain. Cell 59:627–636, 1989.

    PubMed  CAS  Google Scholar 

  57. Resh MD: Specific and saturable binding of pp60v-src to plasma membranes: Evidence for a myristyl-srcreceptor. Cell 58:281–286, 1989.

    PubMed  CAS  Google Scholar 

  58. Sadowski I, Stone JC, Pawson T: A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol 6:4396–4408, 1986.

    PubMed  CAS  Google Scholar 

  59. Pawson T: Non-catalytic domains of cytoplasmic protein-tyrosine kinases: Regulatory elements in signal transduction. Oncogene 3:491–495, 1988.

    PubMed  CAS  Google Scholar 

  60. Wang JYJ, Baltimore D: Localization of tyrosine kinase-coding region in v-abl oncogene by the expression of v-abl-encoded proteins in bacteria. J Biol Chem 260:64–71, 1985.

    PubMed  CAS  Google Scholar 

  61. Koch C, Moran MF, Sadowski I, Pawson T: The common src homology region 2 domain of cytoplasmic signalling proteins is a positive effector of v-fps tyrosine kinase function. Mol Cell Biol 9:4131–4140, 1989.

    PubMed  CAS  Google Scholar 

  62. DeClue JE, Martin GS: Linker insertion-deletion mutagenesis of the v-src gene: Isolation of host-and temperature-dependent mutants. J Virol 63:542–554, 1989.

    PubMed  CAS  Google Scholar 

  63. Mayer BJ, Jackson PK, Baltimore D: High-affinity binding of the noncatalytic SH2 segment of the abl tyrosine kinase to tyrosine-phosphorylated cellular proteins. Proc Natl Acad Sci USA 88:627–631, 1990.

    Google Scholar 

  64. Moran MF, Koch DA, Ellis C, England L, Martin GS, Pawson T: Src homology region 2 domains direct protein-protein interactions in signal transduction. Proc Natl Acad Sci USA 87:8622–8626, 1990.

    PubMed  CAS  Google Scholar 

  65. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S: Oncogenes and signal transduction. Cell 64:281–302, 1991.

    PubMed  CAS  Google Scholar 

  66. Pendergast AM, Traugh JA, Witte ON: Normal cellular and transformation-associated abl proteins share common sites for protein kinase C phosphorylation. Mol Cell Biol 7:4280–4289, 1987.

    PubMed  CAS  Google Scholar 

  67. Kipreos ET, Wang JYJ: Differential phosphorylation of c-Abl in cell cycle determined by cdc2 kinase and phosphatase activity. Science 248:217–220, 1990.

    PubMed  CAS  Google Scholar 

  68. Van Etten R, Jackson P, Baltimore D: Unpublished results.

    Google Scholar 

  69. Prywes R, Foulkes JG, Rosenberg N, Baltimore D: Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation. Cell 34:569–579, 1983.

    PubMed  CAS  Google Scholar 

  70. Watanabe SM, Witte ON: Site-directed deletions of Abelson murine leukemia virus define 3′ sequences essential for transformation and lethality. J Virol 45:1028–1036, 1983.

    PubMed  CAS  Google Scholar 

  71. Ziegler SF, Whitlock CA, Goff SP, Gifford A, Witte ON: Lethal effect of the abelson murine leukemia virus transforming gene product. Cell 27:477–486, 1981.

    PubMed  CAS  Google Scholar 

  72. Goff SP, Tabin CJ, Wang JY-J, Weinberg R, Baltimore D: Transfection of fibroblasts by cloned abelson murine leukemia virus DNA and recovery of transmissible virus by recombination with helper virus. J Virol 41:271–285, 1982.

    PubMed  CAS  Google Scholar 

  73. Jackson P, Van Etten RA, Baltimore D: Unpublished results.

    Google Scholar 

  74. Franz WM, Berger P, Wang JYJ: Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J 8:137–147, 1989.

    PubMed  CAS  Google Scholar 

  75. Jackson PK, Paskind M, Baltimore D: Activation of transforming ability of c-abl by point mutation in the tyrosine kinase domain. Submitted.

    Google Scholar 

  76. Shore SK, Bogart SL, Reddy EP: Activation of murine c-abl protooncogene: Effect of a point mutation on oncogenic activation. Proc Natl Acad Sci USA 87:6502–6506, 1990.

    PubMed  CAS  Google Scholar 

  77. Jackson P, Van Etten RA, Daley GQ, Baltimore D: N-terminal mutations can activate c-abl independent of SH3 mutation N-terminal mutations can activate c-abl independent of SH3 mutation. Submitted, 1991.

    Google Scholar 

  78. Piwinica-worms H, Saunders K, Roberts T, Smith A, Cheng S: Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src. Cell 49:75–82, 1987.

    Google Scholar 

  79. Groffen J, Heisterkamp N, Reynolds FH, Jr., Stephenson JR: Homology between phosphotyrosine acceptor site of human c-abl and viral oncogene products. Nature 304:167–169, 1983.

    PubMed  CAS  Google Scholar 

  80. Jackson P: Unpublished results.

    Google Scholar 

  81. Ponticelli AS, Whitlock CA, Rosenberg N, Witte ON: In vivo tyrosine phosphorylations of the abelson virus transforming protein are absent in its normal cellular homolog. Cell 29:953–960, 1982.

    PubMed  CAS  Google Scholar 

  82. Pendergast AM, Muller AJ, Havlik MH, Clark R, McCormick F, Witte ON: Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci USA 88:5927–5931, 1991.

    PubMed  CAS  Google Scholar 

  83. Konopka JB, Witte ON: Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 5:3116–3123, 1985.

    PubMed  CAS  Google Scholar 

  84. Lugo TG, Pendergast A, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079–1082, 1990.

    PubMed  CAS  Google Scholar 

  85. McWhirter JR, Wang JYJ: Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 11:1785–1792, 1991.

    Google Scholar 

  86. Sporn M, Todaro G: Autocrine secretion and malignant transformation of cells. N Engl J Med 303:878–880, 1980.

    PubMed  CAS  Google Scholar 

  87. Twardzik DR, Todaro GJ, Marquardt H, Reynolds FH, Jr., Stephenson JR: Transformation induced by abelson murine leukemia virus involves production of a polypeptide growth factor. Science 216:894–897, 1982.

    PubMed  CAS  Google Scholar 

  88. Gebhardt A, Bell JC, Foulkes JG: Abelson transformed fibroblasts lacking the EGF receptor are not tumourigenic in nude mice. EMBO J 5:2191–2195, 1986.

    PubMed  CAS  Google Scholar 

  89. Hunter T, Cooper JA: Viral oncogenes and tyrosine phosphorylation. In: The Enzymes. Academic Press, New York, 1986, pp 191–246.

    Google Scholar 

  90. Varticovski L, Daley G, Jackson P, Baltimore D, Cantley L: Activation of PI 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 11:1107–1113, 1991.

    PubMed  CAS  Google Scholar 

  91. Moran MF, Polakis P, McCormick F, Pawson T, Ellis C: Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein. Mol Cell Biol 11:1804–1812, 1991.

    PubMed  CAS  Google Scholar 

  92. Champlin RE, Golde DW: Chronic myelogenous leukemia: Recent advances. Blood 65:1039–1047, 1985.

    PubMed  CAS  Google Scholar 

  93. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1197–1200, 1960.

    Google Scholar 

  94. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293, 1973.

    PubMed  CAS  Google Scholar 

  95. Whang J, Frei III E, Tjio JH, Carbone PP, Brecher G. The distribution of the Philadelphia chromosome in patients with chronic myelogenous leukemia. Blood 22:664–673, 1963.

    PubMed  CAS  Google Scholar 

  96. Tough IM, Jacobs PA, Court-Brown WM, Baikie AG, Williamson ERD: Cytogenetic studies on bone-marrow in chronic myeloid leukaemia. Lancet 1:844–846, 1963.

    PubMed  CAS  Google Scholar 

  97. Allouche M, Bourinbaiar A, Georgoulias V: T-cell lineage involvement in lymphoid blast crisis of chronic myeloid leukemia. Blood 66:1155–1161, 1985.

    PubMed  CAS  Google Scholar 

  98. Kurzrock R, Gutterman J, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990–998.

    Google Scholar 

  99. Clark SS, Crist WM, Witte ON: Molecular pathogenesis of Ph-positive leukemias. Ann Rev Med 40:113–122, 1988.

    Google Scholar 

  100. Daley GQ, Ben-Neriah Y: Implicating the bcrlabl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. In: Advances in Cancer Research. Academic Press, San Diego, 1991, pp 151–184.

    Google Scholar 

  101. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeier A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300:765–767, 1982.

    PubMed  Google Scholar 

  102. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G: Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306:239–242, 1983.

    PubMed  CAS  Google Scholar 

  103. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93–99, 1984.

    PubMed  CAS  Google Scholar 

  104. Collins S, Coleman H, Groudine M: Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells. Mol Cell Biol 7:2870–2876, 1987.

    PubMed  CAS  Google Scholar 

  105. Konopka JB, Watanabe SM, Witte ON: An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035–1042, 1984.

    PubMed  CAS  Google Scholar 

  106. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315:550–554, 1985.

    PubMed  CAS  Google Scholar 

  107. Ben-Neriah Y, Daley GQ, Mes-Masson A-M, Witte ON, Baltimore D: The chronic myelogenous leukemia-specific P210 protein is the product of the bcrlabl hybrid gene. Science 233:212–214, 1986.

    PubMed  CAS  Google Scholar 

  108. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON: Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 235:285–87, 1987.

    Google Scholar 

  109. Hermans A, Heisterkamp N, von Lindern M, van Baal S, Meijer D, van der Plas D, Wiedemann LM, Groffen J, Bootsma D, Grosveld G: Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 51:33–40, 1987.

    PubMed  CAS  Google Scholar 

  110. Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU: Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood 70:1584–1588, 1987.

    PubMed  CAS  Google Scholar 

  111. Selleri L, von Lindern M, Hermans A, Meijer D, Torelli G, Grosveld G: Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript. Blood 75:1146–1153, 1990.

    PubMed  CAS  Google Scholar 

  112. Dreazen O, Canaani E, Gale RP: Molecular biology of chronic myelogenous leukemia. Semin Hematol 25:35–49, 1988.

    PubMed  CAS  Google Scholar 

  113. Chen SJ, Flandrin G, Daniel MT, Valensi F, Baranger L, Grausz D, Bernheim A, Chen Z, Sigaux F, Berger R: Philadelphia-positive leukemia: Lineage promiscuity and inconsistently rearranged breakpoint cluster region. Leukemia 2:261–273, 1988.

    PubMed  CAS  Google Scholar 

  114. Hirsch-Ginsberg C, Childs C, Chang K-S, Beran M, Cork A, Reuben J, Freireich EJ, Chang LCM, Bollum FJ, Trujillo J, Stass SA: Phenotypic and molecular heterogeneity in Philadelphia chromosome-positive acute leukemia. Blood 71:186–195, 1988.

    PubMed  CAS  Google Scholar 

  115. Stam K, Heisterkamp N, Reynolds FH, Jr., Groffen J: Evidence that the phi gene encodes a 160,000-dalton phosphoprotein with associated kinase activity. Mol Cell Biol 7:1955–1960, 1987.

    PubMed  CAS  Google Scholar 

  116. Timmons MS, Witte ON: Structural characterization of the bcr gene product. Oncogene 4:559–567, 1989.

    PubMed  CAS  Google Scholar 

  117. Hariharan IK, Adams JA: cDNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukaemia. EMBO J 6:115–119, 1987.

    PubMed  CAS  Google Scholar 

  118. Diekmann D, Brill S, Garrett MD, Totty N, Hsuan J, Monfries C, Hall C, Lim L, Hall A: Bcr encodes a GTPase-activating protein for p21racc. Nature 351:400–402, 1991.

    PubMed  CAS  Google Scholar 

  119. MÜller AJ, Young JC, Pendergast A, Pondel M, Landau NR, Littman DR, Witte ON: BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive leukemias. Mol Cell Biol 11:1785–1792, 1991.

    PubMed  Google Scholar 

  120. Pendergast AM, MÜller AJ, Havlik MH, Maru Y, Witte ON: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66:161–171, 1991.

    PubMed  CAS  Google Scholar 

  121. Hariharan IK, Adams JM, Cory S: bcr-abl oncogene renders myeloid cell line factor independent: Potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res 3:387–399, 1988.

    PubMed  CAS  Google Scholar 

  122. Daley G, Baltimore D: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210 bcrlabl protein. Proc Natl Acad Sci USA 85:9312–9316, 1988.

    PubMed  CAS  Google Scholar 

  123. Laneuville P, Heisterkamp N, Groffen J: Expression of the chronic myelogenous leukemia-associated p210 bcrlabl oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene 6:275–282, 1991.

    PubMed  CAS  Google Scholar 

  124. Daley GQ, McLaughlin J, Witte ON, Baltimore D: The CML-specific P210 bcrlabl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 237:532–535, 1987.

    PubMed  CAS  Google Scholar 

  125. Lugo TG, Witte ON: The bcr-abl oncogene transforms rat-1 cells and cooperates with v-myc. Mol Cell Biol 9:1263–1270, 1989.

    PubMed  CAS  Google Scholar 

  126. McLaughlin J, Chianese E, Witte ON: In vitro transformation of immature hematopoietic cells by the P210 bcrlabl oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84:6558–6562, 1987.

    PubMed  CAS  Google Scholar 

  127. Young JC, Witte ON: Selective transformation of primitive lymphoid cells by the bcrlabl oncogene expressed in long-term lymphoid or myeloid cultures. Mol Cell Biol 8:4079–4087, 1988.

    PubMed  CAS  Google Scholar 

  128. McLaughlin J, Chianese E, Witte ON: Alternative forms of the bcrlabl oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 9:1866–1874, 1989.

    PubMed  CAS  Google Scholar 

  129. Scherle PA, Dorshkind K, Witte ON: Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function. Proc Natl Acad Sci USA 87:1908–1912, 1990.

    PubMed  CAS  Google Scholar 

  130. Rosenbaum H, Harris AW, Bath ML, McNeall J, Webb E, Adams JM, Cory S: An E(mu)-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J 9:897–905, 1990.

    PubMed  CAS  Google Scholar 

  131. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J: Acute leukemia in bcr/abl transgenic mice. Nature 344:251–253, 1990.

    PubMed  CAS  Google Scholar 

  132. Hariharan IK, Harris AW, Crawford M, Abud H, Webb E, Cory S, Adams JM: A bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol 9:2798–2805, 1989.

    PubMed  CAS  Google Scholar 

  133. Grosveld G: Personal communication.

    Google Scholar 

  134. Elefanty AG, Hariharan IK, Cory S: bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multiple hematopoietic neoplasms in mice. EMBO J 9:1069–1078, 1990.

    PubMed  CAS  Google Scholar 

  135. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 247:824–830, 1990.

    PubMed  CAS  Google Scholar 

  136. Daley GQ, Van Etten RA, Baltimore D: Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci USA 88:11335–11338, 1991.

    PubMed  CAS  Google Scholar 

  137. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc Natl Acad Sci USA 87:6649–6653, 1990.

    PubMed  CAS  Google Scholar 

  138. Scott ML, Van Etten RA, Daley GQ, Baltimore D: v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc Natl Acad Sci USA 88:6506–6510, 1991.

    PubMed  CAS  Google Scholar 

  139. Chung S-W, Wong PMC, Durkin H, Wu Y-S, Petersen J: Leukemia initiated by hemopoietic stem cells expressing the v-abl oncogene. Proc Natl Acad Sci USA 88:1585–1589, 1991.

    PubMed  CAS  Google Scholar 

  140. Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N: Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol Cell Biol 11:4710–4716, 1991.

    PubMed  CAS  Google Scholar 

  141. Van Etten RA, Daley GQ, in preparation.

    Google Scholar 

Download references

Authors
  1. Richard A. Van Etten
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Research Institute, University of California, San Francisco, USA

    Christopher C. Benz

  2. Lineberger Cancer Research Center, The University of North Carolina at Chapel Hill, USA

    Edison T. Liu

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Van Etten, R.A. (1993). Malignant transformation by abl and BCR/ABL . In: Benz, C.C., Liu, E.T. (eds) Oncogenes and Tumor Suppressor Genes in Human Malignancies. Cancer Treatment and Research, vol 63. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3088-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3088-6_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6349-1

  • Online ISBN: 978-1-4615-3088-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation